Navigation Links
Hill-Rom Reports Second Quarter Financial Results
Date:5/4/2009

January 2009, lower Liko margins associated with the valuation of acquired inventories and Liko integration costs. Adjustments in the prior year include costs associated with the spin-off of the funeral services business, primarily a stock modification charge and a loss on the extinguishment of debt. Unless otherwise indicated, amounts in the current quarter include the results of Liko, acquired on October 1, 2008.

Management Comments

"Consistent with our previous outlook, U.S. hospital and extended care customers continued to take a very cautious view toward capital spending as a result of recessionary concerns, yet our International and Post Acute businesses held steady. Our sales results also suggest that Hill-Rom is faring about the same as other capital equipment-intensive medical technology companies," commented Peter H. Soderberg, president and CEO of Hill-Rom. "In spite of the current softness in U.S. hospital capital equipment demand, we are maintaining our on-going multi-year growth strategy, while accelerating our efforts to reduce costs in both supply chain and other expense areas. We are pleased with the first six months of performance by our new Liko unit, and continue to integrate this business into our global and cross-continuum businesses as anticipated. We believe these efforts will position the company for future growth in anticipation of a return to more normalized customer demand."

Soderberg continued, "As a result of our manufacturing, service, and operating expense cost control initiatives, gross profit and operating profit margins, as adjusted, expanded both sequentially and year-over-year. We limited the decline in adjusted operating income to 2.2 percent, while only slightly reducing our investments in selling and R&D. While we cannot predict the timing of when hospitals and other providers will return to more normalized capital acquisition behavior, we should be wel
'/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Hill-Rom to Present at the Bank of America 2009 Health Care Conference
2. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast
3. JCR and Hill-Rom Name First Nurse Scholar-in-Residence
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
6. Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year
7. DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 First Quarter Earnings Webcast
9. Hill-Rom Reports First Quarter Revenue of $350 Million and Announces Further Actions to Address Challenging Economic Environment
10. JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program
11. Hill-Rom Announces First Quarter 2009 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3